In the latest trading session, Novavax (NVAX) closed at $4.33, marking a +0.93% move from the previous day. This move outpaced the S&P 500's daily loss of 1.57%. Elsewhere, the Dow saw a downswing of ...

In a letter seen by MarketWatch, the activist fund blamed the sharp drop in Novavax’s sales on the U.S. vaccine-maker’s ...

Former Massachusetts Institute of Technology and Whitehead Institute of Biomedical Research biologist David Sabatini, who ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novavax ( NVAX 2.06%) was once a top-performing vaccine stock, soaring more than 2,000% in 2020 on optimism about its ...

Here’s your go-to guide with everything you need to know about COVID-19, including testing expanding to more airports, ...

Also, subunit vaccine technology, which uses purified protein antigens derived from the target pathogen, is being used to ...

Harmony Biosciences is adding a suite of epilepsy assets to its pipeline, buying Epygenix for $35 million upfront with more ...

Data presented at ESCMID Global 2024 highlights the efficacy of vaccines against malaria, Streptococcus pneumoniae and more.

A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an ...

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The ...

Q1 earnings growth expectations have sharply declined more than usual as we enter earnings season. Over the past three months, Q1 growth projections have been adjusted downward by 21.5 percentage ...